Shed (ShedRx) Review: The Advertised Price Is a 12-Month Rate

Shed — the company that used to trade as ShedRx, and whose old domain now redirects to the new one — reaches a site about sleep peptides through two different doors, and it is worth separating them before anything else. One is a longevity line: compounded sermorelin, NAD+ in three delivery routes, glutathione, methylene blue and low-dose naltrexone. That is squarely the territory this site covers, and it is why Shed already holds a row on our sermorelin board. The other is a GLP-1 weight-loss programme, which is not a sleep treatment and is here for one specific, limited reason we set out below. Different products, different arguments, and we would rather say which is which than let the on-thesis half launder the adjacent half.

Then there is the price, which is the finding that matters most. Shed's own banner reads "Compounded Semaglutide as low as $159/mo" and "Compounded Trizepatide starting as low as $239/mo" — the typo is theirs. Neither figure is a monthly price. Both are what a month costs if you commit to twelve of them. Month to month, semaglutide is $199 and tirzepatide is $299, and you do not have to take our word for that: the company's own terms of service print both numbers.

The advertised price is a twelve-month rate

Shed publishes a proper three-rung ladder on each product page, which is more than several competitors do. What it advertises everywhere else is only the bottom rung.

Compounded semaglutide, weekly injection:

• •1 month — $199/month. The real ongoing price.
• •6 months — $179/month (Shed labels the saving $120).
• •12 months — $159/month (labelled a $480 saving). This is the advertised number.

Compounded tirzepatide, weekly injection:

• •1 month — $299/month. The real ongoing price.
• •6 months — $269/month (labelled a $180 saving).
• •12 months — $239/month (labelled a $720 saving). This is the advertised number.

The arithmetic is honest — $40 a month off, twelve times over, really is $480 — and the ladder really is on the page. The headline is what misleads: a twelve-month commitment rate wearing a per-month suffix, quoted as though it were the price of starting. If you compare Shed's $239 against another provider's month-to-month figure you are comparing a year's commitment against someone else's rate, which is precisely the mistake that made us re-check every advertised number on our price-sorted board.

The confirmation is in Shed's own Terms and Conditions, section 13.1, describing what happens when a multi-month plan runs out: the subscription "will automatically convert to and renew on a monthly or 28-day basis at the then-current standard rate (currently $199 per month for Compounded Semaglutide and $299 per month for Compounded Tirzepatide)." The company knows exactly what its monthly price is. It just does not put it on the front page.

One detail inside that same sentence is worth its own moment: "monthly or 28-day". A 28-day billing cycle is thirteen charges a year, not twelve. At $299 that is an extra $299 a year against what "per month" implies, and Shed does not say which cycle you will be on.

"Month to month" still means two months minimum

This one is worth separating from the ladder above, because it is a different problem and it applies to every product Shed sells — including the sermorelin and NAD+ lines, which have no ladder at all. Their monthly prices genuinely are the recurring rate. What is not true anywhere on this site is that you can buy one month.

Section 11.1 of the terms: "All programs require a minimum commitment of two (2) full months. Early cancellation within this period does not release you from payment obligations and will not result in a refund or credit." Section 10 repeats it and section 11.4 makes it non-refundable. So the smallest decision available is twice the monthly figure — $398 for semaglutide, $598 for tirzepatide, $398 for sermorelin, $288 for NAD+ nasal spray. That is the number to weigh, not the one on the button.

The other side of the ledger is genuinely good, and rarer than it should be. Cancellation is by a link in the member portal, a link in any billing email, or an email to support — and the terms commit in writing that Shed "will not require you to complete a retention offer, discount offer, or additional customer-service interaction as a condition of cancellation." Anyone who has tried to leave a telehealth subscription knows how unusual that sentence is. The catch is timing: cancellations must land at least 72 hours before the next billing or shipment date, or they apply to the following cycle.

A last piece of multi-month arithmetic that is easy to miss. Under a twelve-month subscription the terms say you receive forty-eight weeks of medication, and under a six-month plan twenty-four weeks — four weeks per vial, one injection a week. Forty-eight weeks is not a year. At $159 a month for twelve months you pay $1,908 for 48 weekly doses, which is $39.75 a dose; at the $199 monthly rate a four-week cycle is $49.75 a dose. The discount is real, roughly 20%, but it is smaller than the $159-versus-$199 headline gap suggests once you count doses rather than months.

The 120-day guarantee has four conditions attached — and covers one product line

Shed's most prominent promise is a 120-day weight-loss guarantee: lose 5% of your baseline weight or reach your enrolment goal weight within 120 days, or get your money back. It is a real, written commitment — section 16.1 of the terms — and it refunds the total you actually paid during that window, shipped medication included. Most competitors offer nothing of the kind.

Note what it is a guarantee of. The endpoint is weight loss, so it applies to the GLP-1 programme and not to sermorelin, NAD+ or anything else in the longevity line. If you are here for the peptide rather than the weight-loss drug, the guarantee on the banner is not a guarantee you are buying.

It is also conditional on four Member Commitments, all four of which you must complete:

• •Attend all four monthly coaching appointments with a Shed health coach.
• •Log at least two weight entries per calendar month — eight over the period.
• •Complete at least 50% of daily check-ins — 60 of the 120 days — in the company's app.
• •Submit every provider follow-up form by its due date and stay in good standing.

Eligibility is verified "primarily from objective system records… and not by member self-attestation alone", and claims must be filed within 30 days of the window closing. None of that is unreasonable — a weight-loss guarantee with no engagement requirement would be unfundable. But sixty daily app check-ins is a real obligation, not a formality, and the headline "or your money back" does not hint at it. If the guarantee is part of why you are signing up, treat those four commitments as the actual terms of the deal and diarise them from day one.

One more inconsistency to note, because it appeared on the same page on the same day: the homepage carries both "Lose 5% of your weight in 120 days or your money back" and, further down, "Lose 10% of your body weight or your money back." The terms say 5% (or your enrolment goal weight). Go by the terms.

The brand-name lane is a membership, not a price

Shed lists brand-name Wegovy, Zepbound and Foundayo (orforglipron, the daily GLP-1 pill) alongside the compounded line, and those are FDA-approved products rather than compounded ones — a meaningful distinction we come back to below. But the way they are sold is not what the price tag suggests.

The brand pages read "Starting at $149/month + additional $125/month Shed Membership." Read the two halves. The terms are explicit that "the membership fee is separate from the cost of medication," "Shed does not dispense or sell medication directly," and "members are responsible for purchasing approved prescriptions directly through LillyDirect or NovoCare." So the $149 is the manufacturer's own cash price, and what you are buying from Shed is the $125-a-month wrapper around it — clinician access, coaching, refill management. The realistic floor is $274 a month, and only $125 of it is what Shed is charging you.

That is a defensible product. It is not a $149 product, and the way the two figures are stacked in one line invites exactly that misreading. Two further cautions: membership fees are non-refundable once you have been approved for treatment (refundable only if you are not approved), and one of Shed's own Wegovy pricing cards still shows "$99/month", a figure that matches no tier described anywhere else on the site. When a company prints three different numbers for one product on one page, the one to trust is the one in the terms.

Sermorelin — the part of Shed this site actually ranks

Shed sells compounded sermorelin at $199 a month for a one-month supply, and does something most of our board does not: it publishes the dosing schedule, five injections a week rather than nightly. That matters more than it sounds. Two $199 programmes running five and seven doses a week are not the same purchase, and only one of them tells you which you are getting. It is why Shed holds a row on our guide to the best sermorelin providers at all, and $199 is where our price-sorted board puts it — mid-to-upper, not cheap.

Two caveats on that figure. It is a starting price, so a titrated dose may not stay there, and the mcg strength behind it is not published — which means it is not fully comparable against another provider's monthly figure. And there is a template artefact on the page worth naming so nobody is misled by it: the sermorelin page also renders a hero reading "Buy Sermorelin Online — Starting at $149/month" attached to copy about an FDA-approved GLP-1 pen and pill. That block is the Wegovy template bleeding through the site's CMS; the sermorelin pricing card says $199, and $149 is not a sermorelin price at Shed.

On the clinical side, Shed's sermorelin copy is better than the category average. Its own FAQ describes sermorelin as a GHRH analogue that "stimulates the pituitary gland to naturally produce more growth hormone" rather than replacing it — an accurate description of the mechanism, and the one our evidence review of sermorelin for sleep and recovery works through. It publishes real contraindications (active cancer, pituitary disorders, pregnancy and breastfeeding, diabetes and insulin resistance), which several storefronts do not, and states plainly that compounded medications are not reviewed or approved by the FDA. The claim that would not survive a close read is calling it "a safer and more physiologic option" than synthetic growth hormone: the mechanism argument for preferring a secretagogue is reasonable, but there is no comparative safety trial behind the word safer, and modern long-term outcome data in healthy adults simply do not exist³.

One thing Shed does not do is dose in the evening by default and market it for sleep. If sleep is your reason for wanting sermorelin, the honest evidence is that GHRH given to healthy men does measurably increase slow-wave sleep alongside the expected GH release² — a real effect, and a narrower one than most marketing implies. Before starting anything here, read who should not take sermorelin and get a baseline drawn: sermorelin labs and IGF-1 monitoring explains why the number from before is the one you cannot get later.

NAD+, and the headline pattern that repeats

The rest of the longevity line is what makes Shed genuinely relevant here rather than merely adjacent, and NAD+ is the biggest part of it. Shed sells it in three routes, which almost nobody does: nasal spray at $144 a month, injections at $169, oral tablets at $169. Choice of route is a real convenience, and if you already take a GH peptide at night, an oral or nasal option is a materially different proposition from a second injection.

Two things to keep hold of. First, the pricing headline behaves exactly as it does on the GLP-1 side: the page leads with "Starting at $144", which is the nasal spray — the cheapest of the three routes, not the injectable most people picture when they read "NAD+". Same pattern, different mechanism: on the GLP-1s the headline is the longest commitment, here it is the least-absorbed format. Second, the evidence bar. Shed's own copy is careful — it says NAD+ is "designed to help support healthy levels" and lists no outcome claim — and that restraint is appropriate, because compounded NAD+ in any route has no outcome trial behind it. It is a supplement-shaped purchase sold on a prescription pathway.

A contradiction about where the medicine comes from

This one is worth more than the price detail, and it applies to the sermorelin as much as to anything else, because the same terms govern every product.

The NAD+ page says the products are "Prepared by U.S.-based, accredited compounding pharmacies following strict quality standards." Section 37 of the terms of service says something different: "Shed makes no representations or guarantees regarding any medication or other product's place of origin. Medications and other products may be shipped to you directly from sources other than within the United States, including without limitation the United Kingdom, Canada, and other locations."

We are not going to reconcile those, because they do not reconcile. One is marketing copy on a product page and the other is the contract you agree to at checkout, and when a company's marketing and its terms disagree the terms are the part that is enforceable. For a compounded product the facility is most of the quality question — which is the same reason we mark Shed's unnamed compounding pharmacy against it on the board. If it matters to you where your medicine is made, ask before you order and get the answer in writing, because the document you have already signed reserves the company's right to ship it from anywhere.

Why a GLP-1 company appears on a sleep site at all

Be exact about this, because that half of the adjacency is narrow. A GLP-1 is not a sleep treatment. There is one route by which it becomes relevant to a reader here: obstructive sleep apnea. Weight loss is the intervention with the strongest effect on OSA severity, and tirzepatide carries an FDA approval for moderate-to-severe OSA in adults with obesity — the only drug that does. Our GLP-1 for sleep apnea page lays out what that trial actually showed, including the part sellers tend to blur: the approval belongs to brand Zepbound, not to compounded tirzepatide, which has never been tested for apnea. Shed's compounded tirzepatide is the cheaper product and it is not the approved one.

If your sleep is broken for any other reason, a GLP-1 is not the tool, and neither is a growth-hormone peptide — the argument we make at length in sermorelin and sleep apnea. And if you are weighing the two categories against each other, sermorelin and semaglutide is the honest comparison: the GLP-1 trials are large and replicated¹, the sermorelin evidence is not in the same universe, and the two are not substitutes. Either way, apnea is a diagnosis that requires a sleep study. Get tested before you buy anything for it.

What Shed discloses about itself, and what it doesn't

More than most. The site is owned and operated by Shed Holdings, LLC, of South Jordan, Utah — a named entity with a named address in its own terms, which is more corporate identity than several companies on our board offer. It carries a LegitScript certification seal for tryshed.com, served live from LegitScript's own domain. And we screened Shed against the FDA's warning-letter database on 7 August 2026 and found nothing on record for Shed, ShedRx or Shed Holdings — a verified clean result, checked on the same search that returns letters for three other companies we cover.

Less than we would like. The clinicians are described only as an "independent, physician-owned or licensed professional" Provider Group; no medical director is named. The compounding pharmacy is never named either — the terms say only that prescriptions are "fulfilled and shipped by a third-party dispensing pharmacy" — and a compounded product is only as good as the facility that makes it. No state list is published on the site; the offer listing we work from says all fifty, so treat that as the working answer and confirm it at intake before paying. The outcome figures on the homepage ("over 1,250,000 pounds lost", "9.8% weight loss") are footnoted as self-reported member data, which Shed to its credit says outright — but self-reported customer data is not a trial endpoint, and the before-and-after testimonials are first-party.

Finally, the format menu is the widest we track: injections, liquid drops at $229/month, sublingual lozenges at $199/month, a microdose tier from $149, plus the brand lane. Two of those deserve a flag. The drops and lozenges are compounded formats whose absorption has not been established the way the injectable's has — the same argument we make about oral and sublingual sermorelin. And the $149 microdose is a sub-therapeutic dose, not a cheaper version of the full one; it is the lowest number on the site and it does not buy the thing the trials studied.

Bottom line

Shed publishes a real ladder rather than a single opaque figure, commits in writing to a cancellation process with no retention gauntlet, names the entity behind it, carries a LegitScript seal, is clean on the FDA's warning-letter database as of August 2026, and — unusually for a GLP-1 operator — sells a sermorelin product with its dosing schedule published, which is why it is on our board at all.

Against that, two separate problems that are easy to blur together. On the GLP-1 injectables, the advertised $159 and $239 are twelve-month rates; month to month it is $199 and $299, and the company's own terms say so. On the longevity line there is no ladder and the monthly price is real — but every programme on the site carries a two-month minimum you cannot refund, so the smallest purchase is always twice the number on the button. Billing may also run on 28-day cycles, and a twelve-month plan buys 48 weeks rather than 52.

The rest: the 120-day guarantee is real, requires four commitments including sixty daily check-ins, and covers weight loss only — not the peptide. The brand-name lane is $149 of manufacturer pricing plus a separate $125-a-month membership, with the medication bought from LillyDirect or NovoCare rather than from Shed. The pharmacy and the prescribing clinicians are unnamed, no state list is published, and the terms reserve the right to ship from outside the United States while the product pages advertise U.S. compounding.

Budget the monthly figure and then double it, because two months is the real unit of purchase here. If you genuinely intend to stay twelve, the commitment rungs are honestly priced and clearly shown — just make that decision on month one's evidence rather than on a banner.